Similar articles

• Evaluation of long-term oral levodopa therapy in chronic congestive heart failure.

  Hasenfuss G, Kasper W, Meinertz T, Busch W, Lehmann M, Krause T, Hofmann T, Revenaugh M, Holubarsch C, Just H. Hasenfuss G, et al. Klin Wochenschr. 1987 Nov 16;65(22):1087-94. doi: 10.1007/BF01736115. Klin Wochenschr. 1987. PMID: 3121909
• The use of levodopa, an oral dopamine precursor, in congestive heart failure.

  Broderick G, Rajfer SI. Broderick G, et al. Basic Res Cardiol. 1989;84 Suppl 1:187-90. doi: 10.1007/BF02650358. Basic Res Cardiol. 1989. PMID: 2818455
• Hemodynamic and clinical effects of oral levodopa in children with congestive heart failure.

  Mendelsohn AM, Johnson CE, Brown CE, Chance WT, Beekman RH 3rd. Mendelsohn AM, et al. J Am Coll Cardiol. 1997 Jul;30(1):237-42. doi: 10.1016/s0735-1097(97)00109-5. J Am Coll Cardiol. 1997. PMID: 9207648
• Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine.

  Rajfer SI, Anton AH, Rossen JD, Goldberg LI. Rajfer SI, et al. N Engl J Med. 1984 May 24;310(21):1357-62. doi: 10.1056/NEJM198405243102105. N Engl J Med. 1984. PMID: 6717507
• Catecholamine metabolism in patients with congestive heart failure under acute and chronic oral levodopa therapy.

  Lehmann M, Hasenfuss G, Holubarsch C, Kasper W, Meinertz T. Lehmann M, et al. Arzneimittelforschung. 1990 Mar;40(3):233-6. Arzneimittelforschung. 1990. PMID: 2346532